{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T18:06:34Z","timestamp":1707588394256},"reference-count":25,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2021]]},"DOI":"10.3960\/jslrt.21001","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T22:07:14Z","timestamp":1620943634000},"page":"114-119","source":"Crossref","is-referenced-by-count":3,"title":["Burkitt leukemia with precursor B-cell features that developed after                    ruxolitinib treatment in a patient with hydroxyurea-refractory                        &lt;i&gt;JAK2&lt;\/i&gt;&lt;sup&gt;V617F&lt;\/sup&gt;-myeloproliferative                    neoplasm"],"prefix":"10.3960","volume":"61","author":[{"given":"Katsuhiro","family":"Fukutsuka","sequence":"first","affiliation":[{"name":"Tenri                    Institute of Medical Research, Nara,                    Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Futoshi","family":"Iioka","sequence":"additional","affiliation":[{"name":"Department of                    Hematology, Tenri Hospital,                    Nara, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiyo","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Tenri                    Institute of Medical Research, Nara,                    Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Tenri                    Institute of Medical Research, Nara,                    Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiyuki","family":"Kishimori","sequence":"additional","affiliation":[{"name":"Tenri                    Institute of Medical Research, Nara,                    Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Hayashida","sequence":"additional","affiliation":[{"name":"Tenri                    Institute of Medical Research, Nara,                    Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Tagawa","sequence":"additional","affiliation":[{"name":"Department of                    Hematology, Tenri Hospital,                    Nara, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Akasaka","sequence":"additional","affiliation":[{"name":"Department of                    Hematology, Tenri Hospital,                    Nara, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen","family":"Honjo","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Surgical Pathology, Tenri                    Hospital, Nara,                Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ohno","sequence":"additional","affiliation":[{"name":"Tenri                    Institute of Medical Research, Nara,                    Japan,"},{"name":"Department of                    Hematology, Tenri Hospital,                    Nara, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Leoncini L, Campo E, Stein H, et al. Burkitt                    lymphoma. In: Swerdlow SH, Campo E, Harris NL, <i>et al<\/i>. (eds).                    WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised                    4th edition, Lyon, IARC, 2017; pp. 330-334."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Wagener R, L\u00f3pez C, Kleinheinz K <i>et al.<\/i>                    IG-MYC+ neoplasms with precursor                        B-cell phenotype are molecularly distinct from Burkitt                        lymphomas.                    Blood. 2018; 132:                        2280-2285.","DOI":"10.1182\/blood-2018-03-842088"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Li Y, Gupta G, Molofsky A <i>et al.<\/i>                    B Lymphoblastic leukemia\/lymphoma with Burkitt-like morphology                        and IGH\/MYC rearrangement: report of 3 cases in adult                        patients.                    Am J Surg Pathol. 2018; 42:                        269-276.","DOI":"10.1097\/PAS.0000000000000982"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Yoon J, Yun JW, Jung CW <i>et al.<\/i>                    Molecular characteristics of terminal deoxynucleotidyl                        transferase negative precursor B-cell phenotype Burkitt leukemia with                        IGH-MYC rearrangement.                    Genes Chromosomes Cancer. 2020;                        59: 255-260.","DOI":"10.1002\/gcc.22825"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Komrokji R, Lancet J, Felgar R, Wang N, Bennett JM.                        Burkitt\u2019s leukemia with precursor B-cell                        immunophenotype and atypical morphology (atypical Burkitt\u2019s                        leukemia\/lymphoma): case report and review of literature.                    Leuk Res. 2003; 27:                        561-566.","DOI":"10.1016\/S0145-2126(02)00271-0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Navid F, Mosijczuk AD, Head DR <i>et al.<\/i>                    Acute lymphoblastic leukemia with the (8;14)(q24;q32)                        translocation and FAB L3 morphology associated with a B-precursor                        immunophenotype: the Pediatric Oncology Group experience.                    Leukemia. 1999; 13:                        135-141.","DOI":"10.1038\/sj.leu.2401244"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Sakaguchi K, Imamura T, Ishimaru S <i>et al.<\/i>                    Nationwide study of pediatric B-cell precursor acute                        lymphoblastic leukemia with chromosome 8q24\/ MYC                        rearrangement in Japan.                    Pediatr Blood Cancer. 2020; 67:                        e28341.","DOI":"10.1002\/pbc.28341"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Shiratori S, Kondo T, Fujisawa S <i>et al.<\/i>                    c-myc rearrangement in B-cell lymphoblastic lymphoma with the                        involvement of multiple extranodal lesions.                    Leuk Lymphoma. 2011; 52:                        716-718.","DOI":"10.3109\/10428194.2010.551158"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Slavutsky I, Andreoli G, Guti\u00e9rrez M <i>et al.<\/i>                    Variant (8;22) translocation in lymphoblastic                        lymphoma.                    Leuk Lymphoma. 1996; 21:                        169-172.","DOI":"10.3109\/10428199609067595"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Rumi E, Barat\u00e8 C, Benevolo G <i>et al.<\/i>                    Myeloproliferative and lymphoproliferative disorders: state of                        the art.                    Hematol Oncol. 2020; 38:                        121-128.","DOI":"10.1002\/hon.2701"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Porpaczy E, Tripolt S, Hoelbl-Kovacic A <i>et al.<\/i>                    Aggressive B-cell lymphomas in patients with myelofibrosis                        receiving JAK1\/2 inhibitor therapy.                    Blood. 2018; 132:                        694-706.","DOI":"10.1182\/blood-2017-10-810739"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Pemmaraju N, Kantarjian H, Nastoupil L <i>et al.<\/i>                    Characteristics of patients with myeloproliferative neoplasms                        with lymphoma, with or without JAK inhibitor therapy.                    Blood. 2019; 133:                        2348-2351.","DOI":"10.1182\/blood-2019-01-897637"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Maffioli M, Giorgino T, Mora B <i>et al.<\/i>                    Second primary malignancies in ruxolitinib-treated myelofibrosis:                        real-world evidence from 219 consecutive patients.                    Blood Adv. 2019; 3:                        3196-3200.","DOI":"10.1182\/bloodadvances.2019000646"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Rumi E, Zibellini S, Boveri E <i>et al.<\/i>                    Ruxolitinib treatment and risk of B-cell lymphomas in                        myeloproliferative neoplasms.                    Am J Hematol. 2019; 94:                        E185-E188.","DOI":"10.1002\/ajh.25489"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Rumi E, Passamonti F, Elena C <i>et al.<\/i>                    Increased risk of lymphoid neoplasm in patients with                        myeloproliferative neoplasm: a study of 1,915 patients.                    Haematologica. 2011; 96:                        454-458.","DOI":"10.3324\/haematol.2010.033779"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Holst JM, Plesner TL, Pedersen MB <i>et al.<\/i>                    Myeloproliferative and lymphoproliferative malignancies occurring                        in the same patient: a nationwide discovery cohort.                    Haematologica. 2020; 105:                        2432-2439.","DOI":"10.3324\/haematol.2019.225839"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Akasaka T, Akasaka H, Ohno H.                        Polymerase chain reaction amplification of long DNA targets:                        application to analysis of chromosomal translocations in human B-cell                        tumors                    [review].                    Int J Oncol. 1998; 12:                        113-121.","DOI":"10.3892\/ijo.12.1.113"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Akasaka T, Lee YF, Novak AJ <i>et al.<\/i>                    Clinical, histopathological, and molecular features of                        mucosa-associated lymphoid tissue (MALT) lymphoma carrying the t(X;14)                        (p11;q32)\/ GPR34 -immunoglobulin heavy chain                        gene.                    Leuk Lymphoma. 2017; 58:                        2247-2250.","DOI":"10.1080\/10428194.2017.1289525"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Lay M, Mariappan R, Gotlib J <i>et al.<\/i>                    Detection of the JAK2 V617F mutation by                        LightCycler PCR and probe dissociation analysis.                    J Mol Diagn. 2006; 8:                        330-334.","DOI":"10.2353\/jmoldx.2006.050130"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Pasqualucci L, Neumeister P, Goossens T <i>et al.<\/i>                    Hypermutation of multiple proto-oncogenes in B-cell diffuse                        large-cell lymphomas.                    Nature. 2001; 412:                        341-346.","DOI":"10.1038\/35085588"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Lieber MR.                        Mechanisms of human lymphoid chromosomal                        translocations.                    Nat Rev Cancer. 2016; 16:                        387-398.","DOI":"10.1038\/nrc.2016.40"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Tsai AG, Lu H, Raghavan SC <i>et al.<\/i>                    Human chromosomal translocations at CpG sites and a theoretical                        basis for their lineage and stage specificity.                    Cell. 2008; 135:                        1130-1142.","DOI":"10.1016\/j.cell.2008.10.035"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Tsai AG, Lu Z, Lieber MR.                        The t(14;18)(q32;q21)\/IGH-MALT1 translocation in MALT                        lymphomas is a CpG-type translocation, but the t(11;18)(q21;q21)\/API2-MALT1                        translocation in MALT lymphomas is not.                    Blood. 2010; 115:                        3640-3641.","DOI":"10.1182\/blood-2010-01-265157"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Greisman HA, Lu Z, Tsai AG <i>et al.<\/i>                    IgH partner breakpoint sequences provide evidence that AID                        initiates t(11;14) and t(8;14) chromosomal breaks in mantle cell and Burkitt                        lymphomas.                    Blood. 2012; 120:                        2864-2867.","DOI":"10.1182\/blood-2012-02-412791"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Arcaini L, Cazzola M.                        Benefits and risks of JAK inhibition.                    Blood. 2018; 132:                        675-676.","DOI":"10.1182\/blood-2018-07-858720"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/2\/61_21001\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T05:28:19Z","timestamp":1622870899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/2\/61_21001\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.21001","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}